Methylation Profiling Identifies Stability of Isocitrate Dehydrogenase Mutation Over Time
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · 2024
DOI: 10.1017/cjn.2023.253 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2024. Verfasst von Mathew R Voisin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Mutation, Brain Neoplasms, Glioma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Objective
Isocitrate dehydrogenase (IDH) mutation status is a key diagnostic and prognostic feature of gliomas. It is thought to occur early in glioma tumorigenesis and remain stable over time. However, there are reports documenting a loss of IDH mutation status in a subset of patients with glioma recurrence. Here, we identified patients with a documented loss of IDH mutation status longitudinally and performed multi-platform analysis in order to determine if IDH mutations are stable throughout glioma evolution.
Methods
We retrospectively identified patients from our institution from 2009 to 2018 with immunohistochemistry (IHC)-recorded IDH mutation status changes longitudinally. Archived formalin-fixed paraffin-embedded and frozen tissue samples from these patients were collected from our institution’s tumour bank. Samples were analysed using methylation profiling, copy number variation, Sanger sequencing, droplet digital PCR (ddPCR) and IHC.
Results
We reviewed 1491 archived glioma samples including 78 patients with multiple IDH mutant tumour samples collected longitudinally. In all instances of documented loss of IDH mutation status, multi-platform profiling identified a mixture of low tumour cell content and non-neoplastic tissue including perilesional, reactive or inflammatory cells.
Conclusions
All patients with a documented loss of IDH mutation status longitudinally were resolved through multi-platform analysis. These findings support the hypothesis that IDH mutations occur early in gliomagenesis and in the absence of copy number changes at the IDH loci and are stable throughout tumour treatment and evolution. Our study highlights the importance of accurate surgical sampling and the role of DNA methylome profiling in diagnostically uncertain cases for integrated pathological and molecular diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada.
- MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada.
- Department of Laboratory Medicine and Pathobiology, Laboratory Medicine Program, University Health Network, University of Toronto, Toronto, ON, Canada.
ORCID-Profile: Mathew R Voisin, Chloe Gui, Andrew F Gao
Förderung
- NCI NIH HHS
Zitieren
APA
Voisin, M. R., Gui, C., Patil, V., Gao, A. F., & Zadeh, G. (2024). Methylation Profiling Identifies Stability of Isocitrate Dehydrogenase Mutation Over Time. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. https://doi.org/10.1017/cjn.2023.253
Vancouver
Voisin MR, Gui C, Patil V, Gao AF, Zadeh G. Methylation Profiling Identifies Stability of Isocitrate Dehydrogenase Mutation Over Time. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 2024. doi:10.1017/cjn.2023.253
BibTeX
@article{Voisin2024,
author = {Voisin, Mathew R and Gui, Chloe and Patil, Vikas and Gao, Andrew F and Zadeh, Gelareh},
title = {Methylation Profiling Identifies Stability of Isocitrate Dehydrogenase Mutation Over Time},
journal = {Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques},
year = {2024},
doi = {10.1017/cjn.2023.253}
}
EUVIMED